Eisai R&d Management Co., Ltd.

Daniel Custar

Jing Li

Hyeong-wook Choi

Yimin Jiang

Wanjun Zheng

Hong Du

Jaemoon Lee

Robert Yu

Xiaojie Zhu

Maarten Postema

Frank Fang

Earl Albone

Toshimitsu Uenaka

Xin Cheng

Utpal Majumder

Keiji Furuuchi

Francis Gerard Fang

Hyeong-Wook Choi

We provide compounds given by Formula I, which is shown in FIG., or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.

EP4 antagonists

Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

Eribulin-based antibody-drug conjugates and methods of use

Growing community of inventors

North Andover, MA, United States of America

Daniel Custar